主要先進国における膠芽腫（Glioblastoma Multiforme）治療市場（～2019）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Introduction 8
2.2 Classification of Brain Tumors 9
2.3 Tumor Grading 11
2.4 Subtypes of Glioblastoma Multiforme 12
2.5 Etiology 12
2.6 Pathophysiology 13
2.6.1 Loss of Heterozygosity of Chromosome 10 14
2.6.2 Epidermal Growth Factor Receptor Amplification 14
2.6.3 Phosphatase and Tensin Homolog Mutation 14
2.6.4 Loss of p53 Function 15
2.6.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function 15
2.6.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation 15
2.7 Symptoms 16
2.8 Diagnosis 17
2.9 Prognosis 18
2.10 Epidemiology 19
2.11 Treatment options 20
2.11.1 Surgery 20
2.11.2 Radiotherapy 20
2.11.3 Chemotherapy 21
2.11.4 Targeted Therapy 22
2.11.5 Drugs for symptoms relief 22
2.11.6 Other alternative therapies 22
2.12 Treatment algorithm 23
3 Marketed drugs 26
3.1 Temodar (temozolomide) – Merck 26
3.2 Avastin (bevacizumab) – Roche 28
3.3 BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) 30
3.3.1 BiCNU (carmustine) – Bristol-Myers Squibb 31
3.3.2 Gliadel Wafer (carmustine in polifeprosan) – Eisai 32
3.4 Unlicensed/Off-label Use in Glioblastoma Multiforme 34
3.4.1 Lomustine 34
3.4.2 Carboplatin 34
3.4.3 Cyclophosphamide 34
3.4.4 Etoposide 35
3.4.5 Irinotecan 35
3.5 Comparative Efficacy and Safety 35
3.6 Unmet needs 38
4 Glioblastoma Pipeline 40
4.1 Overall Pipeline 40
4.2 Molecular Targets 42
4.3 Clinical Trials 44
4.3.1 Clinical Trial Size 44
4.3.2 Clinical Trial Duration 46
4.3.3 Failure Rate of Developmental Pipeline 48
4.3.4 Summary of Clinical Trial and Risk Analysis 50
4.4 Promising Pipeline Candidates 50
4.4.1 DCVax-L – Northwest Biotherapeutics 50
4.4.2 Rindopepimut (CDX-110) – Celldex Therapeutics 52
4.4.3 Avastin (bevacizumab)- Roche 53
4.4.4 ICT-107 – ImmunoCellular Therapeutics 55
4.4.5 Cotara- Peregrine Pharmaceuticals 56
4.4.6 Eir-060- EirGen Pharma 57
4.4.7 Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline 57
5 Market forecasts 62
5.1 Geographical Markets 62
5.1.1 Global Market 63
5.1.2 North America 64
5.1.3 Top Five Countries of Europe 69
5.1.4 Japan 73
5.2 Drivers and Barriers 76
5.2.1 Drivers 76
5.2.2 Barriers 77
6 Deals and Strategic Consolidations 79
6.1 Major Co-Development Deals 79
6.1.1 Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical 79
6.1.2 Immatics Biotechnologies Enters into Agreement with Cancer Research UK 79
6.2 Major Licensing Deals 79
6.2.1 ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania 79
6.2.2 Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children’s Hospital Medical Center 80
6.2.3 Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 80
7 Appendix 81
7.1 Sources 81
7.2 Market Definition 90
7.3 Abbreviations 90
7.4 All Pipeline Products, by Phase 93
7.4.1 Discovery 93
7.4.2 Preclinical 95
7.4.3 Phase I 99
7.4.4 Phase II 101
7.4.5 Phase III and Pre-registration 105
7.4.6 Undisclosed stage of development 105
7.5 Tabular Forecast Data 105
7.5.1 Global 105
7.5.2 US 106
7.5.3 Canada 106
7.5.4 UK 107
7.5.5 France 107
7.5.6 Germany 108
7.5.7 Italy 108
7.5.8 Spain 109
7.5.9 Japan 109
7.6 Research Methodology 110
7.7 Coverage 110
7.7.1 Secondary Research 110
7.8 Therapeutic Landscape 110
7.8.1 Forecasting 111
7.9 Geographical Landscape 112
7.10 Pipeline Analysis 112
7.11 Competitive Landscape 112
7.11.1 Expert Panel Validation 112
7.12 Contact Us 112
7.13 Disclaimer 112